TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A Being Patient report describes four leading theories about what causes Alzheimer’s: amyloid buildup, tau tangles, inflammation and vascular damage. The theories explain different parts of the disease, and researchers have not established one complete cause. Treatments targeting amyloid have modestly slowed cognitive decline in trials but are not cures.
Alzheimer’s disease has no single established cause, and researchers are studying four leading explanations: amyloid plaques, tau tangles, inflammation and damage to the brain’s blood vessels. A Being Patient report explains how each theory may contribute to the progressive loss of brain cells, while stressing that none alone fully accounts for the disease.
The report describes Alzheimer’s as a progressive condition that damages and kills neurons, disrupting the connections through which brain cells communicate. Damage often affects the hippocampus, which helps form new memories, before extending to functions including language, judgment and behavior. The source cites the Alzheimer’s Association’s 2026 report, which estimates 7.4 million Americans age 65 and older are living with Alzheimer’s dementia.
The amyloid hypothesis, dominant in research for more than three decades, proposes that beta-amyloid fragments accumulate between neurons and form plaques, potentially setting off further damage. The tau theory focuses on abnormal tau proteins inside neurons: tau normally helps support structures that transport materials through cells, while tangled tau is associated with cell damage. The report also identifies inflammation and vascular damage as leading areas of research, but the supplied material does not detail the evidence or mechanisms behind those two theories.
Drugs targeting amyloid have produced mixed results. The report says FDA-approved Leqembi (lecanemab) and Kisunla (donanemab) modestly slowed cognitive decline in clinical trials among people in early stages of Alzheimer’s; they are not cures and carry risks, including brain swelling and bleeding, requiring monitoring. Aduhelm, an earlier anti-amyloid drug, was discontinued by its maker in 2024 after evidence of clinical benefit was unconvincing, according to the report.
Why Alzheimer’s Causes Matter
Understanding what drives Alzheimer’s could shape how researchers identify people at risk and develop treatments. The amyloid theory has already influenced drug development and diagnostic testing: the report notes that amyloid can be assessed with PET scans and spinal-fluid tests, and that the FDA cleared a blood test to aid identification of amyloid pathology in May 2025.
But the distinction between changing a biological marker and improving a person’s condition matters. The report describes the benefits seen with newer amyloid antibodies as modest slowing of decline, not reversal or prevention of the disease. Their risks and monitoring needs also mean treatment decisions belong with qualified clinicians. The competing theories point to a broader research question: whether Alzheimer’s begins with one process or emerges through several interacting ones.
Alzheimer's amyloid plaque test kit
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
From Plaques to Multiple Theories
In 1906, German psychiatrist Alois Alzheimer described plaques and twisted fibers in the brain of a former patient, Auguste Deter. Those findings are now known as amyloid plaques and tau tangles, the characteristic brain changes associated with Alzheimer’s. Their discovery did not settle what starts the disease or why neurons are lost.
The amyloid explanation became the leading framework for decades and drove substantial drug research. Yet the report notes that some scientists question whether amyloid is only harmful, with some proposing it may have protective functions. The existence of treatments that clear plaques, alongside limited clinical benefits and unresolved questions, has kept attention on other possible mechanisms.
““Both γ-secretase and β-secretase inhibitors, which strongly inhibit amyloid-beta production, worsen cognitive and clinical performance in early and late stages of Alzheimer’s disease.””
— Bruno Imbimbo, researcher at Chiesi Farmaceutici, as quoted by Being Patient
As an affiliate, we earn on qualifying purchases.
What Researchers Have Not Settled
No single theory is confirmed as a complete explanation for why Alzheimer’s begins and progresses. The report presents amyloid, tau, inflammation and vascular damage as leading theories, but the supplied material does not establish how much each contributes, whether one precedes the others, or how they may interact in different patients.
It also remains unclear from the material how well findings about plaques or tangles predict an individual’s symptoms or future course. The modest trial results for amyloid-targeting drugs do not establish that amyloid is irrelevant, but they also do not show that removing plaques alone can stop the disease. Details about the evidence supporting the inflammation and vascular theories are not included in the source excerpt.
brain inflammation monitoring device
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Research Beyond Amyloid Treatments
Researchers continue to test treatments aimed at Alzheimer’s biology, including therapies targeting amyloid and tau, while investigating inflammation and vascular factors. The immediate evidence to watch is whether ongoing and future studies show meaningful benefits for patients, how those benefits compare with treatment risks, and whether combinations of approaches perform better than targeting one process.
For now, the report’s account supports a measured conclusion: Alzheimer’s has recognizable brain changes and several plausible mechanisms, but its full cause remains unknown. No specific next trial result or research milestone is identified in the source material.
As an affiliate, we earn on qualifying purchases.
Key Questions
What are the four leading theories about Alzheimer’s causes?
The report identifies amyloid plaques, tau tangles, inflammation and vascular damage as four leading areas of explanation. They may describe connected or overlapping processes, but no single theory is established as a complete cause.
Are amyloid plaques proven to cause Alzheimer’s?
Amyloid plaques are a hallmark of Alzheimer’s and central to a long-standing theory that they contribute to neuron damage. However, researchers continue to debate amyloid’s role, and the report says some scientists have proposed that it may also have protective functions.
Do Alzheimer’s drugs that target amyloid cure the disease?
No. The report says Leqembi and Kisunla modestly slowed cognitive decline in clinical trials among people in early stages of Alzheimer’s. They are not cures and carry risks, including brain swelling and bleeding, that require monitoring.
Can a blood test diagnose Alzheimer’s?
According to the report, the FDA cleared a blood test in May 2025 to aid in identifying amyloid pathology linked to Alzheimer’s. The source does not describe it as a stand-alone diagnosis; people should discuss testing and results with a qualified health professional.
Source: rss
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
